留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

CYP2C19基因多态性对药物代谢影响的研究进展

彭净 刘卫

彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J]. 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
引用本文: 彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J]. 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
Citation: PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008
基金项目: 山东省药学会奥赛康中青年临床药师资助项目(No.sdpa-ask-2013-02)

Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism

  • 摘要: 药物代谢和相互作用的差异与CYP的单核苷酸基因多态性有关。综述CYP2C19基因多态性对质子泵抑制剂、抗真菌药伏立康唑、抗血小板药氯吡格雷的代谢和药物相互作用的影响,以期为个体化用药提供参考。
  • [1] 吴敏良,吴晓虹,陈枢青. 细胞色素P4502C19 在中国汉族人群不同组织中的分布差异研究[J] .中国药学杂志,2005,40(3):215-218.
    [2] Bertilsson L,Lou YC, Du YU,et al.Pronounced difference between native Chinese and Swedish populations in the polymorphichydroxylation of debrisoquin and S-mephenytoin[J]. Clin Pharmacol Ther, 1992,51(4):388-397.
    [3] Blaisdell J,Mohrenweiser H,Jackson J,et al.Identification and functional characterization of new potentially defective alleles of human CYP2C19[J]. Pharmacogenetics, 2002,12(9):703-711.
    [4] Sim SC, Risinger C, Dahl ML, et al.A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants[J] . Clin Pharmacol Ther,2006,79(1):103-113.
    [5] Xie HG,Huang SL,Xu ZH,et al.Evidence for the effect of gender on activity of S-mephenytoin in a Chinese population[J]. Pharmacogenetics, 1997,7(2):115-119.
    [6] Wedlund PJ,Aslanian WS,McAllister CB,et al.Mephenytoin hydroxylation deficiency in caucasians: frequency of a new oxidative drug metabolism polymorphism [J]. Clin Pharmacol Ther,1984,36(6):773-780.
    [7] Jacquehnes SM, PhamlJ DB, John WF.Determination of CYP2C19 phenotype in black Americans wit homeprazole: correlation with genotype [J]. Clin Pharmacol Ther,1996,60(2):138-144.
    [8] Zhang YX, Wei SJ, Yang XY,et al. Effects of genetic polymorphisms of CYP2C19*2/*3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects[J]. Int J Clin Pharmacol Ther, 2014,52(10):850-855.
    [9] 姜英杰,李瑜元, 聂玉强, 等. 雷贝拉唑根除幽门螺杆菌疗效及其与CYP2C19 基因多态性的关系[J]. 广州医学院学报, 2004, 32(3): 22-25.
    [10] Sezgin O,Barlas IO,Uçbilek E,et al.Modified sequential Helicobacter pylori eradication therapy using high dose omeprazole and amoxicillin in the initial phase in the extensive metaboliser Turkish patients for CYP2C19 polymorphism is ineffective[J].Acta Gastroenterol Belg,2014,77(1):3-7.
    [11] Lee JY,Kim N,Kim MS,et al. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance[J]. Dig Dis Sci,2014,59(6):1235-1243.
    [12] John J,Lima,Jason EL,et al.Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children[J]. Pediatry,2013,163(3):686-691.[13] Varenhorst C,James S, Erlinge D, et al.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not rasugrel in aspirin-treated patients with coronary artery disease[J]. Eur Heart J,2009,30(14):1744-1752.
    [13] Arima Y, Hokimoto S, Akasaka T, et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina[J].J Cardiol,2015,65(6):494-500.
    [14] 谢 婧,杨莉萍,刘 瑶,等.CYP2C19*17基因对氯吡格雷临床疗效影响的Meta分析[J]. 中国药房,2012,23(28):2618-2621.
    [15] Crepeau AZ, Moseley BD, Wirrell EC.Specific safety and tolerability considerations in the use of anticonvulsant medications in children[J].Drug Health Patient Saf,2012,4: 39-54.
    [16] Kouga T, Shimbo H, Iai M,et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome[J]. Brain Dev, 2015,37(2):243-249.
    [17] de Leon J.The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19[J].Clin Psychopharm,2007,27(3):241-245.
    [18] 王瓅珏,唐惠林,段京莉. CYP2C19基因多态性对伏立康唑药代动力学影响的系统评价[J]. 中国临床药理学杂志,2011,29(8):607-611.
    [19] Zonios D,Yamazaki H,Murayama N,et al.Voriconazole metabolism, toxicity and the effect of cytochrome P450 2C19 genotype [J].J Infect Dis,2014,209(12):1941-1948.
    [20] Choi CI,Bae JW,Lee YJ,et al.Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics[J]. J Clin Psychopharmacol, 2014,34(1):139-142.[22] Nastasi-Catanese JA,Padilla-Gutiérrez JR,Valle Y, et al.Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response[J]. Genet Mol Res,2013,12(4):4413-4421.
    [21] Sibbing D,Morath T,Stegherr J,et al.Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel[J]. Thromb Haemost,2009,101(4):714-719.
    [22] Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor[J].Arch Intern Med, 2010,170(8):704-710.[25] 曲彩红,黎小妍. 伏立康唑与奥美拉唑可能的不良相互作用致肌病及肝功能恶化[J]. 药物不良反应杂志,2011,13(6): 374-377.
    [23] Kim DY,Park HJ,Lee YJ.Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections[J]. Int J Clin Pharmacol Ther,2014,52(3):209-216.
    [24] Simon T, Steg PG, Gilard M, et al.Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P4502C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute st-elevation and non-st-elevation myocardial infarction (FAST-MI) registry[J]. Circulation,2011,123(5):474-482.
    [25] Furuta T,Iwaki T,Umemura K. Influences of different proton pump inhibitors on the antiplatelet function of clopidogrel in relation to CYP2C19 genotypes[J] . Br J Clin Pharmacol, 2010, 70(3):383-392.
    [26] Collet JP, Hulot JS, Anzaha G, et al. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (clopidogrel and response variability investigation study 2) [J].JACC Cardiovasc Interv,2011,4(4):392-402.
    [27] Wallentin L,James S,Storey RF,et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J].Lancet,2010,376(9749):1320-1328.
    [28] Mega JL,Close SL,Wiviott SD,et al.Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes[J]. Circulation,2009, 119(9):2553-2560.
    [29] Erlinge D,James S,Duvvuru S,et al.Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease[J].Thromb Haemost,2014,111(5):943-950.
  • [1] 谢小云, 黄爱文, 李莉, 江彦, 蔡佳松.  药物基因多态性对替格瑞洛抗血小板聚集效果的影响 . 药学实践与服务, 2023, 41(10): 629-633, 642. doi: 10.12206/j.issn.2097-2024.202207087
    [2] 黄琴, 索南格勒, 李文斌, 孙月梅, 王荣.  阿托伐他汀的基因多态性研究进展 . 药学实践与服务, 2022, 40(5): 416-421, 426. doi: 10.12206/j.issn.2097-2024.202110042
    [3] 桂明珠, 李静, 谢晓恬, 李志玲.  伏立康唑治疗儿童侵袭性真菌感染血药浓度与疗效相关性研究 . 药学实践与服务, 2022, 40(4): 359-363. doi: 10.12206/j.issn.1006-0111.202106075
    [4] 王亚妮, 吴迪, 饶志, 李茂星, 葸瑞, 任俊.  异基因造血干细胞移植患者体内环孢素A和伏立康唑的相互作用 . 药学实践与服务, 2022, 40(3): 277-280. doi: 10.12206/j.issn.1006-0111.202111056
    [5] 刘艳辉, 董婧, 陆燕, 卢曼, 丁云鹤, 李文艳.  SLCO1B1 521 T>C和APOE基因多态性对阿托伐他汀调脂疗效及安全性的影响 . 药学实践与服务, 2021, 39(3): 245-248. doi: 10.12206/j.issn.1006-0111.202012013
    [6] 侯文洁, 张亮, 李翔宇, 王洁.  CYP2C19基因多态性对PCI术后患者氯吡格雷血药浓度、血小板抑制率和安全性的影响 . 药学实践与服务, 2021, 39(5): 472-475. doi: 10.12206/j.issn.1006-0111.202008029
    [7] 张艳霞, 陈泉金, 宋洪涛.  环孢素注射液在肾移植患者中的血药浓度与基因多态性的相关性研究 . 药学实践与服务, 2020, 38(4): 334-339. doi: 10.12206/j.issn.1006-0111.201911107
    [8] 毛旭峰, 杨樟卫.  质子泵抑制剂临床超适应证使用的医疗大数据分析 . 药学实践与服务, 2020, 38(2): 184-188. doi: 10.3969/j.issn.1006-0111.201909086
    [9] 张喆, 蔡卫民.  UGT1A1基因多态性对药物代谢和临床作用影响的进展 . 药学实践与服务, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
    [10] 张红楠, 王强, 朱晓红, 郎轶咏.  CYP2C19基因指导冠心病患者经皮冠状动脉介入术后抗血小板药合理应用 . 药学实践与服务, 2018, 36(6): 518-521. doi: 10.3969/j.issn.1006-0111.2018.06.009
    [11] 胡乔乔, 何佳.  不同剂量氯吡格雷对脑梗死患者神经功能的影响 . 药学实践与服务, 2017, 35(5): 449-452. doi: 10.3969/j.issn.1006-0111.2017.05.016
    [12] 黄瑾, 曾颖, 唐帆, 袁芳.  中药及其活性成分与氯吡格雷抗血小板聚集的相互作用 . 药学实践与服务, 2016, 34(5): 389-392,398. doi: 10.3969/j.issn.1006-0111.2016.05.002
    [13] 颜苗, 王柠柠, 李紫薇, 蒋梦飞, 王峰, 张毕奎, 徐萍, 肖轶雯.  伏立康唑血药浓度监测结果评析 . 药学实践与服务, 2016, 34(5): 421-423,446. doi: 10.3969/j.issn.1006-0111.2016.05.010
    [14] 张燕青, 陈锦珊, 李金雨, 林秀丽, 石鹤坤, 林小凤.  MDR1基因多态性和单倍体对肾移植术后稳定期患者他克莫司浓度/剂量比值的影响 . 药学实践与服务, 2015, 33(5): 415-418. doi: 10.3969/j.issn.1006-0111.2015.05.008
    [15] 叶其蓁, 张南生, 孙卫军, 陈祉旖.  重症颅脑损伤合并胃肠和肺部感染与质子泵抑制剂的关系研究 . 药学实践与服务, 2015, 33(1): 65-67. doi: 10.3969/j.issn.1006-0111.2015.01.018
    [16] 刘丽娜, 刘晓东, 肇丽梅.  1例糖尿病合并侵袭性肺曲霉菌感染患者的药学监护 . 药学实践与服务, 2014, 32(5): 389-392. doi: 10.3969/j.issn.1006-0111.2014.05.022
    [17] 游春华, 熊筱娟, 王清华, 陈万生, 高守红.  维生素D受体基因的多态性与检测方法 . 药学实践与服务, 2014, 32(5): 329-331,392. doi: 10.3969/j.issn.1006-0111.2014.05.003
    [18] 樊蓉, 党大胜, 赵庆春, 史国兵.  临床药师参与处置伏立康唑致血液系统肿瘤患者视觉障碍的临床实践 . 药学实践与服务, 2013, 31(4): 307-309. doi: 10.3969/j.issn.1006-0111.2013.04.020
    [19] 陈子安, 雷招宝.  埃索美拉唑的不良反应与合理用药 . 药学实践与服务, 2010, 28(6): 468-470.
    [20] 侯明明, 宋洪涛, 王庆华, 杨顺良, 谭建明.  肾移植患者MDR1C3435T基因多态性对他克莫司血药浓度/剂量比及疗效的影响 . 药学实践与服务, 2010, 28(1): 29-31.
  • 加载中
计量
  • 文章访问数:  2979
  • HTML全文浏览量:  286
  • PDF下载量:  273
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-05-16
  • 修回日期:  2015-01-20

CYP2C19基因多态性对药物代谢影响的研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.008
    基金项目:  山东省药学会奥赛康中青年临床药师资助项目(No.sdpa-ask-2013-02)

摘要: 药物代谢和相互作用的差异与CYP的单核苷酸基因多态性有关。综述CYP2C19基因多态性对质子泵抑制剂、抗真菌药伏立康唑、抗血小板药氯吡格雷的代谢和药物相互作用的影响,以期为个体化用药提供参考。

English Abstract

彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J]. 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
引用本文: 彭净, 刘卫. CYP2C19基因多态性对药物代谢影响的研究进展[J]. 药学实践与服务, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
Citation: PENG Jing, LIU Wei. Research progress in the effect of CYP2C19 gene polymorphisms on drug metabolism[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 508-512. doi: 10.3969/j.issn.1006-0111.2015.06.008
参考文献 (29)

目录

    /

    返回文章
    返回